Advaxis CEO and leadership

CEO with nearly 30 years of diverse experience predominately in general management and business development. Background in both high-value diagnostics and therapeutics with management experience covering numerous areas including general management, sales and marketing, business development, strategic planning, research & development, commercial assessment and portfolio management.

Andres A Gutierrez works at HOSPITAL ANGELES DEL PEDREGAL SA DE CV and a Chief Medical Officer at ADVAXIS, INC. and Exec VP/Chief Medical Ofcr at ADVAXIS, INC. and is based in New York City, New York. He has worked as Medical Director, Clinical Development & MA at SONOMA PHARMACEUTICALS, INC.; Chief Medical Officer at SELLAS Life Sciences; and Medical Director, Clinical Sciences at SUNESIS PHARMACEUTICALS INC. Andres works or has worked at Annica Holdings Ltd and works or has worked as Chief Medical Officer at Sellas Life Science Group. He studied at National University of Mexico, UNAM; Hammersmith Hospital, London UK; and National Medical Center CMR-IMSS-UNAM.

Igor Gitelman joined Cancer Genetics, Inc. in 2017 as principal accounting officer (Chief Accounting Officer). Prior to joining the Company, Mr. Gitelman served as an AVP of Finance and Tax at clinical diagnostic laboratory, BioReference Laboratories, Inc., from October 2005 to October 2016. Mr. Gitelman was also a senior manager of tax and financial reporting at Gucci Group from May 2003 to May 2005 where he managed all aspects of the company’s tax planning, compliance and audits on federal, state and international levels as well as the company’s tax accounting function. He holds a BBA and an MBA degree in accounting form Pace University’s Lubin School of Business.

CEO with nearly 30 years of diverse experience predominately in general management and business development. Background in both high-value diagnostics and therapeutics with management experience covering numerous areas including general management, sales and marketing, business development, strategic planning, research & development, commercial assessment and portfolio management.